UY38137A - Una forma de dosificación oral sólida farmacéutica de solifenacina - Google Patents

Una forma de dosificación oral sólida farmacéutica de solifenacina

Info

Publication number
UY38137A
UY38137A UY0001038137A UY38137A UY38137A UY 38137 A UY38137 A UY 38137A UY 0001038137 A UY0001038137 A UY 0001038137A UY 38137 A UY38137 A UY 38137A UY 38137 A UY38137 A UY 38137A
Authority
UY
Uruguay
Prior art keywords
dosage form
solifenacin
oral dosage
solid oral
solid
Prior art date
Application number
UY0001038137A
Other languages
English (en)
Spanish (es)
Inventor
Villarreal Ana Purón
Munárriz Ainara Lecumberri
Original Assignee
Intas Third Party Sales 2005 S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intas Third Party Sales 2005 S L filed Critical Intas Third Party Sales 2005 S L
Publication of UY38137A publication Critical patent/UY38137A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Physiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UY0001038137A 2018-03-08 2019-03-06 Una forma de dosificación oral sólida farmacéutica de solifenacina UY38137A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382149 2018-03-08
EP18382472 2018-06-26

Publications (1)

Publication Number Publication Date
UY38137A true UY38137A (es) 2019-07-31

Family

ID=65598664

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038137A UY38137A (es) 2018-03-08 2019-03-06 Una forma de dosificación oral sólida farmacéutica de solifenacina

Country Status (5)

Country Link
JP (1) JP2021526504A (ja)
MX (1) MX2020009204A (ja)
TW (1) TW201938163A (ja)
UY (1) UY38137A (ja)
WO (1) WO2019170795A1 (ja)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008128028A2 (en) * 2007-04-11 2008-10-23 Dr. Reddy's Laboratories Ltd. Solifenacin compositions
EP1728791A4 (en) 2004-03-25 2008-12-10 Astellas Pharma Inc COMPOSITIONS FOR SOLID PHARMACEUTICAL PREPARATION OF SOLIFENACIN OR BZW. A SALT OF IT
WO2005105045A1 (ja) 2004-04-30 2005-11-10 Astellas Pharma Inc. 経口投与用時限放出型粒子状医薬組成物及び該組成物を含有する口腔内速崩壊錠
PL2572717T3 (pl) * 2010-05-19 2016-12-30 Kompozycja farmaceutyczna zawierająca solifenacynę

Also Published As

Publication number Publication date
JP2021526504A (ja) 2021-10-07
WO2019170795A1 (en) 2019-09-12
TW201938163A (zh) 2019-10-01
MX2020009204A (es) 2021-01-15

Similar Documents

Publication Publication Date Title
ECSP17013617A (es) “combinación farmacéutica que comprende 3-(3-dimetilamino-1-etil-2-metil-propil)-fenol y nsaid”
EA201591751A1 (ru) Трипептидные эпоксикетонные ингибиторы протеазы
CL2019001366A1 (es) Formulaciones tamponadas exendina (9-39).
MX2024010140A (es) Nuevos metodos.
JP2015517488A5 (ja)
RU2017116740A (ru) Комбинации для лечения рассеянного склероза
SI2889033T1 (en) Treatment of negative symptoms of schizophrenia with (R) -7-chloro-N- (chonylidin-3-yl) benzo (B) thiophene-2-carboxamide and pharmaceutically acceptable salts thereof
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales
PH12019502651A1 (en) Use of vibegron to treat overactive bladder
JP2016512817A5 (ja)
BR112019003136A2 (pt) forma de dosagem multiunitária de composição farmacêutica, forma de dosagem unitária de composição farmacêutica, forma de dosagem multiunitária / unitária, kit e método de tratamento de uma condição tratável por administração oral de um agente terapeuticamente ativo
IL292655A (en) Combined therapy of c-c cytokine receptor type 9 (ccr9) inhibitors and integrin-blocking anti-alha4beta7 antibodies
AR099299A1 (es) Inhibidor de la proteína de transferencia de éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden dicho inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares
TR201819662T4 (tr) Çocukluk çağı hipertansiyon tedavisinde kullanılan enalapril içeren ağızda dağılan film bileşimi.
CL2019002808A1 (es) Métodos para prevenir o tratar enfermedades oftálmicas.
EA202090445A1 (ru) ПРОТИВОГРИБКОВЫЕ СРЕДСТВА С ПОВЫШЕННОЙ АКТИВНОСТЬЮ ПРИ КИСЛОМ pH
UY38137A (es) Una forma de dosificación oral sólida farmacéutica de solifenacina
AR114378A1 (es) Una forma de dosificación oral sólida farmacéutica de solifenacina
MX2013001279A (es) Composicion farmaceutica con un inhibidor selectivo de la enzima fosfodiesterasa en forma de gel oral.
RU2015122833A (ru) Способ лечения хронического эндометрита
AR115883A1 (es) Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción
AR068608A1 (es) Neramexano para el tratamiento de nistagmo
AR108792A1 (es) Composiciones que comprenden timolol
RU2016147455A (ru) Способ лечения кожных проявлений склеродермии
CL2017003143A1 (es) Composición multi-péptido.